Device type · LJB
Enzyme Linked Immunoabsorbent Assay, Rubeola Igg
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
LJB
Microbiology
Device class
Class I
FDA decisions since 2015
0
510(k), De Novo and PMA
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- Enzyme Linked Immunoabsorbent Assay, Rubeola Igg
- Product code
- LJB
- Device class
- Class I
- Review panel
- Microbiology
- Regulation
- 21 CFR 866.3520
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for LJB
Latest FDA decisions
No 510(k), De Novo or PMA decisions for this product code since 2015.
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
No reports to chart for this view.
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
No manufacturers to rank.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
No device problems coded.
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
No patient problems coded.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0534-2026 · Started Oct 1, 2025 · Posted by FDA Nov 17, 2025
Reason given: Due to distributing the measles IgG IVD without a premarket approved/cleared.
Cause as FDA categorized it: No Marketing Application
- VIDAS CLINICAL VIDAS MEASLES IGG 60TESTS, CATALOG 30219Open, Classified
Z-0796-2023 · Started Nov 9, 2022 · Posted by FDA Jan 4, 2023
Reason given: As the temperature and time out of range was exceeded, product performances cannot be guaranteed
Cause as FDA categorized it: Storage
- VIDAS Measles IgG (MSG), REF 30219Open, Classified
Z-0430-2022 · Started Sep 22, 2021
Reason given: bioMerieux has been receiving an increasing number of complaints linked to a VIDAS substrate error. It prevents the test from being run, therefore leads to potential delayed results as the user must run another test.
Cause as FDA categorized it: Nonconforming Material/Component
4 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.